| HIV Infections
Biktarvy vs Prezista
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Biktarvy vs Prezista with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrezista has a higher rate of injection site reactions vs Biktarvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prezista but not Biktarvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Biktarvy
Prezista
At A Glance
Oral
Daily
INSTI + NRTI combination
Oral
Once daily or Twice daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections - adults and pediatric >= 25 kg One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; on hemodialysis days, administer after hemodialysis completion.
HIV Infections - pediatric 14 kg to < 25 kg One tablet (30 mg BIC/120 mg FTC/15 mg TAF) taken orally once daily with or without food.
HIV Infections - virologically-suppressed pregnant individuals One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; monitor viral load closely due to lower drug exposures during pregnancy.
HIV-1 Infections (treatment-naive adults) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, no darunavir resistance) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, at least one darunavir resistance substitution) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pregnant patients) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pediatric patients, 3 to less than 18 years) Weight-based dosing with ritonavir, oral, with food. Dosage based on body weight and resistance status, not to exceed adult dose
Contraindications
- Co-administration with dofetilide due to potential for increased dofetilide plasma concentrations and serious or life-threatening events
- Co-administration with rifampin due to substantially decreased BIC plasma concentrations, which may result in loss of therapeutic effect and development of resistance
- Co-administration with alfuzosin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin
- Co-administration with simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil for pulmonary arterial hypertension
- Co-administration with orally administered midazolam
- Co-administration with triazolam
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, angioedema, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria, weight increased
Most common (>=5%, treatment-naive) Diarrhea, headache, abdominal pain, rash, nausea, vomiting
Most common (>=5%, treatment-experienced) Diarrhea, nausea, rash, abdominal pain, vomiting
Serious Hepatotoxicity, severe skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis), acute pancreatitis, diabetes mellitus, hyperglycemia, immune reconstitution syndrome
Postmarketing Rhabdomyolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, crystal nephropathy, crystalluria
Pharmacology
BIKTARVY is a fixed-dose combination antiretroviral containing bictegravir (BIC), an integrase strand transfer inhibitor (INSTI) that blocks integration of HIV-1 DNA into host genomic DNA, plus emtricitabine (FTC) and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs) that terminate viral DNA chain elongation by competing with natural nucleoside substrates.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Biktarvy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Prezista
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Biktarvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Prezista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Biktarvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Prezista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BiktarvyView full Biktarvy profile
PrezistaView full Prezista profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.